Novartis Tunes Into Radiopharmaceuticals With Endocyte Buy
Executive Summary
Endocyte paid just $12m upfront a year ago for a potential first-in-class investigational radioligand therapy for prostate cancer. Novartis is buying Endocyte for a whopping $2.1bn., highlighting the company's emphasis on building in radiopharmaceuticals.
You may also be interested in...
Lead From The Front – But Resist Micromanaging
Theragnostics’ CEO Greg Mullen aims to use his wide-ranging “hands-on” scientific and commercial experience to help clinch a $45m series A financing round that will fund a Phase I/II basket study to develop the biotech’s lead radiotherapeutic PARP inhibitor.
The Medicines Company Rises On Novartis Takeover Rumors
It's been a good week for the US company with its PCSK9 gene-silencing drug impressing at the American Heart Association meeting and reports that Novartis is close to making a bid.
Novartis' New Oncology CEO Schaffert Has A Potential Blockbuster Launch On Her Hands
In an interview at Novartis' research campus in Cambridge, Mass., Schaffert spoke about the upcoming launch of Piqray for breast cancer, building in radiopharmaceuticals, Kymriah's ongoing manufacturing challenges and more.
Need a specific report? 1000+ reports available
Buy Reports